Wolfgang is Managing Partner of Carlyle Global Advisors after a successful career as serial entrepreneur in healthcare. He has developed a network of relationships with accomplished family offices in both the United States and internationally that share a passion for impact Investing and philanthropy in the life sciences and whom he advises from time to time in healthcare related investments. He has successfully helped build and exited from several life science companies to-date principally in the areas of neurological disease, cardiovascular disease and oncology related innovation. Wolfgang holds a M.S. in Physics from University of Gӧttingen and a PhD from Technical University Hamburg-Harburg, both in Germany. Wolfgang is also an active angel investor with Keiretsu in Palo Alto, CA.
Mark M. Davis, Ph.D. is Professor at Stanford University. He is well known for identifying the first T-cell receptor genes. He has authored over 350 publications and received numerous awards and honors for his work, including memberships in the National Academy of Sciences, The National Academy of Medicine and the Royal Society. He is an Investigator with the Howard Hughes Medical Institute and holds the Avery Family Chair of Immunology at the Stanford University School of Medicine. He has been vice chair and chair of the Department of Microbiology and Immunology at Stanford and, since 2004, The Director of the Institute for Immunity, Transplantation and Infection, which has become an international leader in the development of transformative technologies and approaches to better understanding the human immune system and its responses to infectious diseases and autoimmunity.
David Furman, PhD - Founder & Chief Scientific Officer
David is the Director of the Stanford 1000 Immunomes Project, Associate Professor at the Buck Institute for Research on Aging, and co-founder at Edifice Health. He received his PhD in Human Biochemistry from the University of Buenos Aires, Argentina, in 2008. His research is focused on better understanding the aging of the immune system. Using the Influenza, A model, David’s research is focused in elucidating the cellular and molecular mechanisms of human immune-senescence to define immunological ‘metrics’ of human health.
During his Postdoc, he conducted cutting-edge research in Data Science and Systems Immunology to answer scientific questions with strong potential for translational medicine, including the effect of immunity in aging and age-related disease. Advances in these areas will provide for improved diagnostic monitoring and therapeutic interventions that will significantly improve the health and lives of many people.
Asli Gozoren - VP Investor Relations & Communications
Asli has over 20 years of experience in the finance industry, specifically in investor relations, corporate finance, and corporate development. Prior to joining Edifice Health Bio, Asli was a Partner at a San Francisco based advisory firm, guiding early stage companies in growth strategies focusing on key issues including cross-border expansion, commercialization, and capital raising initiatives. During her career, she managed the Corporate Finance division of UK based consulting firm Grant Thornton in an emerging market (led +100 clients in multi-million dollar M&A transactions, company valuations and due diligence projects), launched and grew the largest global business angel investment firm Keiretsu Forum to become the leading early stage investment venture in the MENAT region, an led key global initiatives to increase revenue through strategic partnerships and cross border portfolio syndications across the firm’s +50 global offices.
For the past 23 years, Krinx has been delivering results with leadership roles in commercial healthcare sales, marketing and business development, primarily in the areas of cardiovascular disease, oncology and clinical wellness. From being a sales manager/influencer for a mid-size pharma company KOS (acquired by Abbot for $1.5B), advising the C-Suite of hospital CEOs on sales strategy for the largest private hospital organization in the US (HCA) and to building the clinical sales department from the ground up at Boston Heart (acquired by Eurofins for $200M+), where he worked together with CEO Wolfgang Daum, he has made an impact on organizations at all levels. Krinx grew up in Dallas, TX and attended the University of Texas in Austin where he received his BBA in Marketing from the McCombs School of Business.
Anna is passionate about helping people. She applies over 20 years of corporate accounting and financial planning and analysis experience at Fortune 100 multinational companies with her executive education in strategy and marketing to help Iuve, her third healthtech startup, grow as an attractive investment. After starting her stock portfolio at Age 11, Anna is now an angel investor and limited partner of Portfolia. She plans and executes the financial roadmap for ambitious dreams for herself and entrepreneurs. Certificate of Excellence (venture capital, product management, strategy, leadership) from University of California at Berkeley, executive MBA with emphasis in strategy and marketing from University of North Carolina at Chapel Hill, inactive CPA, longtime caregiver.
Robert Tibshirani’s is Professor at Stanford University. His main interests are in applied statistics, biostatistics, and data mining. He is co-author of the books “Generalized Additive Models” (with Trevor Hastie, Stanford), “An Introduction to the Bootstrap” (with Brad Efron, Stanford), and “Elements of Statistical Learning” (with Trevor Hastie and Jerry Friedman, Stanford). His current research focuses on problems in biology and genomics, medicine, and industry. With Stanford collaborator Balasubramanian Narasimhan, he also develops software packages for genomics and proteomics. His most well-known contributions are in the field of Artificial Intelligence and he is sometimes referred to be the father of the field.
Eric Verdin, MD - Board Member & Scientific Advisor
Eric is the president and chief executive officer of the Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctor of Medicine (MD) from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also a professor of medicine at University of California, San Francisco. Dr. Verdin joined the Buck in 2016 after spending the previous 20 years as a senior investigator at the Gladstone Institutes, where he served as associate director from 2004 to 2016.
Dr. Verdin’s laboratory focuses on the role of epigenetic regulators in the aging process. His laboratory was the first to clone a family of enzymes called HDACs, which regulate histone acetylation. Dr. Verdin studies how metabolism, diet, and small molecules regulate the activity of HDACs and sirtuins, and thereby the aging process itself and its associated diseases, including Alzheimer’s. He has published more than 210 scientific papers and holds more than 15 patents. He is a highly cited scientist and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He is an elected member of several scientific organizations, including the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians. He also serves on the advisory council of the National Institute on Drug Abuse at the NIH.
Joseph C. Wu, MD, PhD is Director of the Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine and Radiology. Dr. Wu received his medical degree from Yale. He completed his medicine internship, residency and cardiology fellowship training at UCLA followed by a PhD (Molecular & Medical Pharmacology) in the UCLA STAR program. His clinical activities involve adult congenital heart disease and cardiovascular imaging. His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). Dr. Wu has published over 350 manuscripts with H-index of 91 on Google scholar. Among his trainees, 25 of them are principal investigators in the US or abroad. Dr. Wu has received numerous awards.